Abstract: A hollow spherical cerium dioxide nanomaterial, preparation method and application thereof; wherein the preparation method uses glucose as a carbon source, urea as a precipitant, cerium trichloride as a cerium source, and water as a solvent to prepare a cerium dioxide/carbon composite material by a hydrothermal method, and then, a hollow spherical cerium dioxide nanomaterial with a multi-shell layer structure is obtained by calcination in a muffle furnace. By adjusting the amount of urea and the calcination temperature, a number of shell layers of the material can be adjusted. Moreover, in the nanomaterial, the number of shell layers can be adjusted, large spacing exists between shell layers, specific surface area can be increased, wherein contact area of the material with an electrolyte increases, but also structural collapse caused by a volume expansion of an electrode material during charging and discharging can be alleviated, and the electrochemical performance is effectively improved.

Abstract: An interlayer material for a lithium-sulfur battery, and a lithium-sulfur battery, the interlayer material including electrically conductive MOF modified carbon fiber paper material between the separator and cathode accelerating electron transfer and having catalytic and barrier effect on lithium polysulfides. The paper material is prepared by: pretreatment of the paper by subjecting the carbon fiber paper to hydrophilic treatment; preparation of carbon fiber paper grown with Co3(HITP)2 including: complexing Co2+ and hexaiminotriphenylene on the paper surface, and allowing the product to grow in situ; and removal of structural impurities.

Abstract: The present invention relates to a bismuth tungstate/bismuth sulfide/molybdenum disulfide heterojunction ternary composite material and a preparation method and application thereof. The composite material is composed of bismuth tungstate, bismuth sulfide and molybdenum disulfide in an ordered layered way, Bi2WO6 is an orthorhombic system, Bi2S3 is a p-type semiconductor located on a (130) crystal face, MoS2 is a layered transition metal sulfide located on a (002) crystal face, the whole composite material is of a spherical structure with an unsmooth surface, and a layer of nanosheets uniformly grow on an outer layer. The average particle size of composite materials is in the range of 2.4-2.6 ?m. The spherical Bi2WO6/Bi2S3/MoS2 heterojunction ternary composite material prepared in the present invention has good adsorption of Cr(VI) and high catalytic reduction ability under visible light.

Abstract: A material with pine-branch like samarium oxide/graphene/sulfur gel structure, and a preparation method and use thereof. The material is reduced graphene oxide carrying pine-branch like samarium oxide on the surface to form a cross-linked gel structure, and sulfur is loaded on the gel structure. The preparation method includes: subjecting graphene oxide and a samarium salt to hydrothermal reduction to prepare a reduced graphene oxide/samarium precursor; under an inert atmosphere, thermolysing the reduced graphene oxide/samarium precursor to obtain a reduced graphene oxide/pine-branch like samarium oxide gel; and melting and diffusing the sulfur onto the reduced graphene oxide/pine-branch like samarium oxide gel. The material with pine-branch like samarium oxide/graphene/sulfur gel structure greatly improves the electrochemical performance of lithium-sulfur batteries.

Abstract: Provided is a three-phase dry-type transformer. The three-phase dry-type transformer comprises three single-phase dry-type transformers connected to each other. Each single-phase transformer comprises an incoming line side high-voltage coil and an outgoing line side high-voltage coil, wherein the incoming line side high-voltage coil is provided with an incoming line end and an outgoing line end, and the outgoing line side high-voltage coil is provided with an incoming line end and an outgoing line end. The outgoing line end of the incoming line side high-voltage coil is connected to the incoming line end of the outgoing line side high-voltage coil, such that the incoming line side high-voltage coil and the outgoing line side high-voltage coil are connected in series. Further provided is an assembly method.

Abstract: The present disclosure provides core-shell nickel ferrite, a nickel ferrite@C material and preparation methods and application thereof. The preparation method of the core-shell nickel ferrite includes: preparing nickel iron glycerate ball powder by a solvothermal method; and under an air condition, heating the nickel iron glycerate ball powder at a heating rate of lower than 1.5° C./min to not less than 350° C. for performing calcination to obtain the core-shell nickel ferrite. The preparation method of the nickel ferrite@C material includes: performing a phenolic resin condensation reaction on the core-shell nickel ferrite, resorcinol and formaldehyde to obtain a phenolic resin (RF) coated core-shell nickel ferrite@RF composite material; and in an inert atmosphere, calcining and carbonizing the nickel ferrite@RF composite material to obtain the nickel ferrite@C material.

Abstract: A self-clamping structure for solving a short-circuit resistance problem of amorphous alloy transformers comprises an A-phase coil, a B-phase coil and a C-phase coil which are horizontally arranged, the A-phase coil being in close contact with the B-phase coil, and the B-phase coil being in close contact with the C-phase coil. By using a solidified low-voltage coil as a fastening splint and binding with a high-strength binding strap, the low-voltage coils of the A-phase and the B-phase clamp and fix a weak portion between the A and B phases; and the low-voltage coil of the B-phase and the C-phase clamp and fix a weak portion between the B and C phases. Outer sides of the A- and C-phase coils are each provided with a high-strength insulation splint, so that the splint and the low-voltage coil of corresponding phase constitute the splint pair to clamp and fix the corresponding weak portion.

Abstract: A self-clamping structure for solving a short-circuit resistance problem of amorphous alloy transformers comprises an A-phase coil, a B-phase coil and a C-phase coil which are horizontally arranged, the A-phase coil being in close contact with the B-phase coil, and the B-phase coil being in close contact with the C-phase coil. By using a solidified low-voltage coil as a fastening splint and binding with a high-strength binding strap, the low-voltage coils of the A-phase and the B-phase clamp and fix a weak portion between the A and B phases; and the low-voltage coil of the B-phase and the C-phase clamp and fix a weak portion between the B and C phases. Outer sides of the A- and C-phase coils are each provided with a high-strength insulation splint, so that the splint and the low-voltage coil of corresponding phase constitute the splint pair to clamp and fix the corresponding weak portion.

Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? combinations thereof.

Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

Abstract: The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

Abstract: The present invention relates to compounds of the general formula: wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? combinations thereof.